Results 51 to 60 of about 1,941,316 (288)

2000 [PDF]

open access: yes, 2000
The report on the state of the drugs problem in Europe presents the EMCDDA's yearly overview of the drug phenomenon. This is an essential reference book for policy-makers, specialists and practitioners in the drugs field or indeed anyone seeking the ...

core   +1 more source

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman   +17 more
wiley   +1 more source

Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011–2021Research in context

open access: yesEClinicalMedicine, 2023
Summary: Background: Access to essential cancer medicines is a key determinant of childhood cancer survival. WHO published the Model List of Essential Medicine for Children (EMLc) and updated it every two years since 2007 to promote better access to ...
Lin Bai   +7 more
doaj   +1 more source

Jahresbericht über den Stand der Drogenproblematik in der Europäischen Union - Zusammenfassung und Schwerpunkte [PDF]

open access: yes, 1997
The report on the state of the drugs problem in Europe presents the EMCDDA's yearly overview of the drug phenomenon. This is an essential reference book for policy-makers, specialists and practitioners in the drugs field or indeed anyone seeking the ...

core   +1 more source

Criterion‐Related Validity of the Neuropsychological Quick Assessment for Screening Cognitive, Motor, and Behavioral Impairments in Patients With Pediatric Brain Tumors: An Observational Pilot Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Neuropsychological complications may impair the qualitative prognosis of patients with pediatric brain tumors. However, multifaceted evaluations cannot be conducted in all patients because they are time consuming and burdensome for patients.
Ami Tabata   +9 more
wiley   +1 more source

Tracking leading anti-Candida compounds in plant samples; Plumbago europaea

open access: yesIranian Journal of Microbiology, 2018
Background and Objectives: Due to the importance of finding new and more effective antifungal and antibacterial compounds against invasive vaginitis strains, this study was conducted for fast screening of plant samples.
Marzieh Sobhani   +3 more
doaj  

Essential topical ocular diagnostic drugs for the family practitioner

open access: yesSouth African Family Practice, 2004
No abstract available.
D. Meyer
doaj   +1 more source

2001 [PDF]

open access: yes, 2001
The report on the state of the drugs problem in Europe presents the EMCDDA's yearly overview of the drug phenomenon. This is an essential reference book for policy-makers, specialists and practitioners in the drugs field or indeed anyone seeking the ...

core   +1 more source

Quality of essential drugs in tropical countries: evaluation of antimalarial drugs in the Brazilian Health System

open access: yesRevista da Sociedade Brasileira de Medicina Tropical, 2011
INTRODUCTION: The emergence of drug resistance is one of the main problems concerning malaria treatment. The use of counterfeit and/or substandard antimalarial drugs can contribute to the development of parasite resistance.
Fernando Henrique Andrade Nogueira   +3 more
doaj   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy